A study of Coversin for the treatment of bullous pemphigoid in patients who are refractory to oral steroids
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Coversin (Primary)
- Indications Bullous pemphigoid
- Focus Adverse reactions; Therapeutic Use
- 21 Mar 2018 According to an Akari Therapeutics media release, the company expects to commence this study in first Half of 2018.
- 27 Apr 2017 New trial record
- 24 Apr 2017 According to an Akari Therapeutics media release, the company anticipates data from this trial in fourth quarter of 2018.